Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).
Employees: 125,000
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
39% more first-time investments, than exits
New positions opened: 276 | Existing positions closed: 199
1.37% more ownership
Funds ownership: 86.77% [Q3] → 88.14% (+1.37%) [Q4]
1% more funds holding
Funds holding: 2,530 [Q3] → 2,554 (+24) [Q4]
13% less capital invested
Capital invested by funds: $204B [Q3] → $177B (-$26.9B) [Q4]
19% less repeat investments, than reductions
Existing positions increased: 869 | Existing positions reduced: 1,073
27% less call options, than puts
Call options by funds: $1.06B | Put options by funds: $1.44B
37% less funds holding in top 10
Funds holding in top 10: 115 [Q3] → 72 (-43) [Q4]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$470
10%
upside
Avg. target
$562
31%
upside
High target
$667
55%
upside
11 analyst ratings
8 positive
73%
3 neutral
27%
0 negative
0%
Argus Research David Toung 45% 1-year accuracy 5 / 11 met price target | 10%upside $470 | Buy Maintained | 29 Apr 2025 |
Scotiabank Sung Ji Nam 8% 1-year accuracy 2 / 24 met price target | 41%upside $605 | Sector Perform Maintained | 25 Apr 2025 |
RBC Capital Conor McNamara 17% 1-year accuracy 7 / 41 met price target | 48%upside $637 | Outperform Maintained | 24 Apr 2025 |
UBS Dan Leonard 22% 1-year accuracy 2 / 9 met price target | 17%upside $500 | Buy Maintained | 24 Apr 2025 |
Stifel Daniel Arias 15% 1-year accuracy 3 / 20 met price target | 45%upside $620 | Buy Maintained | 24 Apr 2025 |
Financial journalist opinion
Based on 27 articles about TMO published over the past 30 days
Positive
Seeking Alpha
14 hours ago
3 Of The Cheapest High-Quality Stocks Money Can Buy
Geopolitical risks and economic uncertainty have battered markets, but I view this turmoil as an opportunity to buy high-quality, undervalued stocks. Despite volatility and weak earnings trends, I'm focused on companies trading well below fair value, with strong fundamentals and long-term growth potential. In this article, I highlight three dirt-cheap stocks across different industries that I believe can deliver significant returns in the years ahead.
Positive
Seeking Alpha
1 day ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.
Neutral
Business Wire
2 days ago
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is employing an enhanced platform technology and a new CHO K-1 cell line that can reduce timelines to Investigational New Drug (IND) filing from 13 to nine months, helping biotech and pharmaceutical companies overcome logistical complexities within pre-clinical biologic drug development. The new CHO K-1 cell line is able to deliver up to 8g/L, providing higher protein expression levels and increased.
Positive
Benzinga
6 days ago
Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan
Thermo Fisher Scientific Inc. TMO announced Thursday that it would invest an additional $2 billion in the U.S. over the next four years.
Positive
Seeking Alpha
6 days ago
Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In
Thermo Fisher's updated 2025 guidance shows a $1 EPS, or 4.2% hit from tariffs and government spending cuts. Thermo can mitigate the tariff issues by next year, as its scale gives it options to source from different locations. Despite short-term challenges, Thermo Fisher aims for 7-9% long-term sales growth, leveraging its diverse product range and strategic acquisitions.
Neutral
Business Wire
6 days ago
Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector. As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the.
Positive
Zacks Investment Research
1 week ago
Thermo Fisher's Q1 Earnings Top Estimates, Revenues Beat, Stock Up
TMO continues to advance its growth strategy and trusted partner status with customers in the first quarter of 2025.
Positive
Benzinga
1 week ago
Thermo Fisher Scientific Q1 Earnings Surpass Estimates, CEO Touts 'Strong Performance' Despite Economic Uncertainty
Thermo Fisher Scientific Inc. TMO reported first-quarter 2025 adjusted earnings per share of $5.15 on Wednesday, beating the street view of $5.10.
Positive
Investopedia
1 week ago
Thermo Fisher Tops Q1 Estimates in 'Uncertain Macroeconomic Environment'
Thermo Fisher Scientific (TMO) shares rose Wednesday after the lab equipment and life science solutions firm reported first-quarter results above analysts' expectations.
Neutral
Seeking Alpha
1 week ago
Thermo Fisher Scientific Inc. (TMO) Q1 2025 Earnings Call Transcript
Thermo Fisher Scientific Inc. (NYSE:TMO ) Q1 2025 Earnings Conference Call April 23, 2025 8:30 AM ET Company Participants Rafael Tejada - Vice President, Investor Relations Marc Casper - Chairman, President & Chief Executive Officer Stephen Williamson - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Matt Sykes - Goldman Sachs Jack Meehan - Nephron Research Rachel Vatnsdal - JPMorgan Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 First Quarter Conference Call. [Operator Instructions] I would like to introduce our moderator for the call, Mr.
Charts implemented using Lightweight Charts™